Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.

Vertex is focused on discovering, developing and producing innovative medicines so people with serious diseases can lead better lives. Our scientists don’t see the impossible as an obstacle; …

Jan 13, 2025 · Vertex plans to share Part B full-dose data from the VX-264 Phase 1/2 study in 2025. Vertex is also pursuing alternative approaches to immunosuppression that could be …

The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.

Jan 30, 2024 · Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain – Treatment with VX-548 led to statistically …

Jul 30, 2024 · Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain – FDA grants priority review and assigns a …

Dec 23, 2024 · BOSTON --(BUSINESS WIRE)--Jan. 17, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2023 financial results …

At Vertex, the world’s most talented and passionate people come together to advance science and transform lives, and in return, we invest in them so they can grow and advance their own …

6 days ago · BOSTON--(BUSINESS WIRE)--Jan. 27, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, …

Dec 19, 2024 · Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy – Treatment with the highly selective NaV1.8 pain …